Held Might 13-16.
Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data in 19th CAHR Argos Therapeutics today announced the presentation of data from the Stage 2a trial of AGS-004, demonstrating that the personalized immunotherapy has a positive effect on the genetic diversity of residual HIV virus, and also results in substantially increased time to viral rebound in HIV patients treated with AGS-004 following antiretroviral therapy interruption. The info were discussed within an oral presentation at the 19th Annual Canadian Meeting on HIV/AIDS Research , held Might 13-16, 2010 in Saskatoon, Saskatchewan. Argos programs to initiate a Phase 2b trial in the 1st half of 2010 http://tadalafilfrance.com/le-tadacip.html .
check the following information
Announced today that the US Food and Medication Administration Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available data do not adequately demonstrate that the potential benefits of lorcaserin outweigh the potential dangers, when utilized long-term in a population of obese and overweight individuals to permit marketing approval. Lorcaserin, which Arena has and discovered developed, is designed for weight management, including weight reduction and maintenance of excess weight loss, in sufferers who are obese or sufferers who are over weight and also have at least one weight-related co-morbid condition.